tebu-bio is a European company specialised in providing innovative reagents and laboratory services in Life Sciences

Need an answer now?

Give us a call

01 30 46 39 00

Leave a message, we'll get back to you

Recombinant protein production and purification platform

Contact me

Our expertise ranges from molecular biology, multiplex studies to large scale production of purified recombinant proteins. We are specialized in recombinant protein production, antibodies included, for downstream R&D applications (e.g. functional assay, selection of variants, crystallography...).

Your recombinant protein production project

  • Outsource a part of or your entire protein production project
  • Ideal tool to speed up your protein-based research program
  • Initial feasibility study to ensure selection of the most appropriate strategy
  • Fully customizable service platform for R&D-scale protein purification from prokaryotic (E. coli) or eukaryotic (Hek293 EBNA) cells

Example of a standard project

  • Production optimization step: expression study (multiplex format)
  • Protein production from small to large scale
  • Purification optimization steps: screening of different chromatography strategies and binding-elution conditions (multiplex purification)
  • Protein purification by affinity, ion exchange and/or gel filtration chromatography on AKTA FPLC system
  • QCs and delivery: Coomassie gel, Western Blot, quantitation, aliquoting of sample, Endotoxin level testing (FDA approved LAL test)

Project Management

  • Process expertise
    Steps are customizable and allow for complete project outsourcing in an ISO9001-2008 certified quality management environment
  • Complete transparency
    Project updates are provided weekly by a designated Project Manager and a specific Sales Manager is available for business interactions
  • No strings attached
    Process methods are made available to customers for fast and efficient industrial exploitation with preservation of IP rights


Recently, tebu-bio produced in vitro truncated tau fragments containing the four microtubule binding repeat domain with a P301L mutation in E. coli. This custom recombinant protein has been used in a recent publication by Janssen R&D for the development of a complete tauopathy model associated with neurodegeneration and inflammation. Peeraer et al. Neurobiol Dis. 2015 Jan; 73: 83–95. DOI: 10.1016/j.nbd.2014.08.032


Image credits: PDB ID 3D90 (monomer and dimer), 5AUU, 4TPR